1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Vimian Group AB (publ)
  6. News
  7. Summary
    VIMIAN   SE0015961982

VIMIAN GROUP AB (PUBL)

(VIMIAN)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-07-01 am EDT
49.50 SEK   +0.90%
06/02Press release from the Annual General Meeting in Vimian Group AB (publ) on 2 June 2022
AQ
05/24Vimian Group AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/23Invitation to Vimian's Interim Report for the first quarter of 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vimian : Indical Bioscience, part of the Vimian group, acquires Salmonella and antimicrobial resistance diagnostics company

08/23/2021 | 02:01am EDT

Indical Bioscience, the operating company within Vimian’s Diagnostics segment, has signed an agreement to acquire Check-Points. Check-Points is a Dutch molecular diagnostics company specialising in Salmonella typing for the food and veterinary market as well as antimicrobial resistance detection for human applications.

Check-Points is a Dutch R&D focused company that produces tests for two principal markets – food safety and human antimicrobial resistance. The main component of the business is related to “Check and Trace”, a unique product based on a microarray platform to accurately identify over 300 serotypes of Salmonella. The company, founded in 2002 with annual revenues of approximately EUR 2.3 million, also produces a number of DNA-based tests for the molecular detection of antimicrobial resistance in hospital acquired infections in humans.
 
Through the Salmonella test, the company principally serves producers and labs within the poultry industry as well as food safety labs. The human assays principally target in-hospital laboratories.
 
“The acquisition of Check-Points bolsters our poultry portfolio and direct-to-producer offering but also represents a first step for Indical into food safety and antimicrobial resistance segments. Check-Points has developed strong momentum in its core products and has an exciting R&D pipeline, with highly relevant development expertise that can support new projects within Indical itself. We look forward to working with the Check-Points management team to take advantage of all these opportunities”, says Stefano Santarelli, CEO of Indical Bioscience.
 
“Joining forces with Indical will allow us to extend the worldwide footprint of our unique, innovative products. We are excited about this wonderful opportunity for our company”, says Pieter Vos, CEO of Check-Points.
 
The acquisition will have a marginal impact on Vimian Group AB's earnings per share in the current financial year.
 
About Indical Bioscience
Indical Bioscience, the operating company within Vimian’s Diagnostics segment, is a global leader in the development of complete solutions for molecular and immunological veterinary testing to identify, prevent, monitor, and eradicate animal diseases. The offering is suited to both the livestock and companion animal health markets. The products and workflows for veterinary diagnostics and pathogen research are trusted by lab technicians, vets, and organizations worldwide, including government agencies, laboratories, research institutes, farmers, and producers.

© Modular Finance, source Nordic Press Releases

All news about VIMIAN GROUP AB (PUBL)
06/02Press release from the Annual General Meeting in Vimian Group AB (publ) on 2 June 2022
AQ
05/24Vimian Group AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/23Invitation to Vimian's Interim Report for the first quarter of 2022
AQ
05/05Vimian Group publishes Annual Report for 2021
AQ
05/03Notice of Annual General Meeting in Vimian Group AB (publ)
AQ
04/13Vimian Group acquires product portfolios of veterinary surgical instruments and orthope..
AQ
04/04Vimian Group acquires one of the leading providers of procurement and support services ..
AQ
04/04VIMIAN GROUP AB (OM : VIMIAN) acquired VerticalVet, LLC.
CI
03/16Vimian Group acquires veterinary allergy business in the UK
AQ
03/10Vimian's Interim Report for the fourth quarter of 2021
AQ
More news
Financials
Sales 2022 276 M 287 M 287 M
Net income 2022 34,8 M 36,2 M 36,2 M
Net Debt 2022 235 M 244 M 244 M
P/E ratio 2022 51,5x
Yield 2022 -
Capitalization 1 791 M 1 863 M 1 863 M
EV / Sales 2022 7,35x
EV / Sales 2023 6,05x
Nbr of Employees 700
Free-Float 36,4%
Chart VIMIAN GROUP AB (PUBL)
Duration : Period :
Vimian Group AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIMIAN GROUP AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 4,60 €
Average target price 7,90 €
Spread / Average Target 71,6%
EPS Revisions
Managers and Directors
Fredrik Ullman Chief Executive Officer
Henrik Mikael Halvorsen Chief Financial Officer
Gabriel Fitzgerald Chairman
Mikael Dolsten Director
Frida Westerberg Director
Sector and Competitors
1st jan.Capi. (M$)
VIMIAN GROUP AB (PUBL)-37.62%1 863
ZOETIS-28.61%81 988
ELANCO ANIMAL HEALTH INCORPORATED-27.34%9 776
DECHRA PHARMACEUTICALS PLC-34.31%4 561
BLUESTAR ADISSEO COMPANY-20.86%3 902
VIRBAC-12.84%3 251